2027 Formulary Updates
See EmblemHealth Formularies for 2027 formulary changes and complete formulary information.
Providers and members can also use the Find a Network Pharmacy tool to locate participating pharmacies.
Medical Pharmacy Updates
Enhanced Drug Wastage (EDW) Program
As of Nov. 1, 2026, EmblemHealth implemented an Enhanced Drug Wastage (EDW) Program through Prime Therapeutics™. This medical drug policy initiative is designed to reduce medication waste and promote appropriate dosing of select provider-administered medications.
See Full Story: Enhanced Drug Wastage Program Through Prime Therapeutics
2027 Medical Pharmacy Management Updates
Review the table below to see the impacted drug classes and preferred product changes that take effect Jan. 1, 2027. These updates are intended to support appropriate prescribing, authorization submissions, and patient care planning.
2027 Preferred Medical Pharmacy Products
Drug/Class | Current 2026 Preferred Management | 2027 Recommendation | Provider Action |
Eculizumab | Soliris; Bkemv; Epysqli | Removing Soliris. Bkemv and Epysqli will continue to be available at parity. No preferred biosimilar selection is being implemented at this time. | Use preferred product(s) for new starts and authorization requests, as applicable. |
Trastuzumab | Kanjinti and Ogivri | Ogivri/Trazimera | Use preferred product(s) for new starts and authorization requests, as applicable. |
Bevacizumab | MVASI/ZIRABEV | Mvasi/Zirabev | No provider action needed. Follow current process. |
Rituximab | Ruxience and Riabni | Riabni/Ruxience | No provider action needed. Follow current process. |
LA-Colony Stimulating Factors | Fulphila, Neulasta, and Udenyca | Fulphila, Neulasta, and Udenyca | No provider action needed. Follow current process. |
Denosumab | Bildyos/Jubbonti, Bilprevda/Wyost | Bildyos/Jubbonti, Bilprevda/Wyost | No provider action needed. Follow current process. |
Infliximab | Remicade/Infliximab or Inflectra or Avsola | Remicade/Infliximab or Renflexis | Use preferred product(s) for new starts and authorization requests, as applicable. |
Aflibercept | Parity Eylea/Pavblu | Parity Eylea/Pavblu | No provider action needed. Follow current process. |
Hyaluronic Acid Derivatives | Gel-One and Synvisc/Synvisc One | Gel-One and Synvisc/Synvisc One | No provider action required beyond current process. |
Tocilizumab | Tyenne IV/PFS and Tofidence | Tyenne/Avtozma | Use preferred product(s) for new starts and authorization requests, as applicable. |
Natalizumab | Parity Tyruko/Tysabri | Preferred Tyruko | Use preferred product(s) for new starts and authorization requests, as applicable. |
Advocate+ Pharmacy Match Program Enhancement: IntegratedRx®
As of Oct. 1, 2026, Prime Therapeutics™ updated the Advocate+ Pharmacy Match Program for select oncology and cystic fibrosis specialty medications through IntegratedRx. This program allows eligible members to receive medications through their care center’s in-house pharmacy, helping improve coordination between the pharmacy and treating physician.
See Full Story: Specialty Pharmacy Program Match
Resources: Pharmacy Services and Specialty Pharmacy Information
*The program applies to all fully insured EmblemHealth plans (i.e., Child Health Plus, Essential Plan, individual and family, NYSHIP, large group, and small group) and all EmblemHealth and AdvantageCare Physicians employees. Accredo will remain the specialty pharmacy provider for the New York City Employees PPO plan and certain other programs.
Reminders
Prime Therapeutics™ Is Our Pharmacy Benefits Manager and Utilization Management Vendor for Pharmacy
In 2026, EmblemHealth partnered with Prime Therapeutics™ to deliver pharmacy benefits, medical pharmacy management, and utilization management services.
Beginning Jan. 1, 2026, EmblemHealth:
- Transitioned and consolidated utilization management for medical pharmacy benefits.
- Replaced Express Scripts and Evolent with Prime Therapeutics as the utilization review agent for infusion therapy.
- Updated home infusion preauthorization requirements.
- Eliminated Prime Therapeutics preauthorization requirements for registered nurse visits and per diem codes.
- Updated preauthorization drug lists so they contain only medications requiring review through Prime Therapeutics.
Pharmacy Medical Policies
The following pharmacy medical policies were updated during the year:
- Anti-Obesity Medications.
- Biosimilar Products.
- CAR-T Cell Therapy.
- Gene Therapy Products.
- GLP-1 Receptor Agonists.
- Immune Globulin Products.
- Infusion Therapy Medications.
- Oncology Supportive Care Agents.
- Provider-Administered Specialty Drugs.
- Self-Administered Specialty Drugs.
Learn More: Pharmacy Medical Policies
Site of Service Medical Policy — Infusions and Injectables
The Site of Service Medical Policy — Infusions and Injectables helps members receive appropriate infusion and injectable therapy services in the most clinically appropriate and cost-effective setting, including doctor offices, infusion centers, and home settings when clinically appropriate.
EmblemHealth works with multiple organizations that recommend the most medically appropriate, convenient, and cost-effective site of care for eligible members.
Prior authorization requests should be submitted to Prime Therapeutics™:
Providers may request a real-time, clinical, peer-to-peer discussion during the prior authorization process. If a determination is not agreed upon, appeal rights are available.
Appeal Rights for Site of Service Denials
EmblemHealth respects the care you provide. If your preauthorization request is denied (called an adverse determination) based on our site of service policy(s), you, a member, their representative, or an attorney can appeal our determination. The appeal must be submitted within 180 days of the date of the adverse determination.
You can mail or fax the appeal to the address(es) or number(s) listed below as applicable:
Site of Service Medical Policy – Infusions and Injectables Policy
By phone: 888-447-8175
By mail:
EmblemHealth Plan, Inc.
Grievance and Appeals Unit
P.O. Box 2844
New York, NY 10116-2844
By fax: 866-350-2168
Learn More: Site of Service Medical Policy – Infusions and Injectables
See Full Story: Policy Updates That Impact Where Members Get Care